PSI Launches SYNETIC™ to Speed up Site ID, Startup, and Enrollment in Pivotal Studies

ZUG, Switzerland – [29 January 2026] – PSI CRO, a Swiss-based global full-service contract research organization (CRO), today announced the launch of SYNETIC™, a next-generation AI-powered semantic knowledge platform that empowers sponsors to identify optimal trial sites, minimize startup delays, and predict and eliminate non-enrolling sites.

Underperforming sites are a persistent industry challenge, directly impacting trial timelines and budgets: 37% of sites enroll poorly, and 11% never enroll a single patient.¹ SYNETIC™’s foundation of over 500,000 unique institutions and 3 million study sites across 62 countries equips PSI’s sponsors and operational teams with real-time, data-driven insights into site capabilities, operational efficiency, and patient recruitment performance, ensuring that even the most complex global trials stay on track and meet aggressive timelines.

SYNETIC™ is a new addition to PSI’s award-winning INTELIA™ Clinical Trial Intelligence Platform, which unites operational excellence, predictive analytics, and AI-enabled decision support to optimize every phase of trial planning and execution.

What SYNETIC™ delivers for the industry and PSI sponsors:

• Instant Site Intelligence: Rapid generation of comprehensive site lists with in-depth data on institutional capabilities, workload, and prior performance
• AI-Driven Site Scoring: Automated algorithmic ranking of sites by protocol fit based on enrollment history, therapeutic expertise, and geographic performance
• Agentic AI and Semantic Search: More accurate study matching using sophisticated agentic AI, leveraging Natural Language Processing (NLP) to query SYNETIC™’s data set using semantic search and LLM-augmented reasoning
• Data-driven Site Matching: Enhanced feasibility assessments powered by advanced AI models for targeted outreach to sites most likely to successfully recruit
• Interactive Knowledge Graphs: Predictive analytics based on complex relationships across millions of data points, connecting institutions, investigators, and trial performance
• Real-Time Insights: Evidence-based insights in real time through a next-gen semantic data architecture powered by PSI’s enterprise ontology

“INTELIA™ enables pharma and biotech sponsors to see what works and what doesn’t for their trial before it begins,” said Kirill Soldatov, Head of Process Improvement at PSI. “SYNETIC™ takes this to the next level, by eliminating blind spots in site selection and patient enrollment. It’s not just a platform – it’s a core enabler of PSI’s promise to sponsors: that teams will deliver, on time, every time, even under the most demanding conditions and in any geography.”To learn more about how SYNETIC™ helps clinical teams reduce clinical trial startup timelines and accelerate patient enrollment worldwide, contact our team.

ENDS

For further information, please contact:

PSI
For Media Inquiries
Ashley Collins, Marketing Specialist
E: ashley.stufanocollins@psi-cro.com
T: +1 919-972-9572

Sciad Communications
Jasmin Shearan / Maria Taylor
E: pressteam@sciad.com
T: +44 020 3405 7892

Notes for Editors

About PSI

PSI CRO is a global, full-service contract research organization committed to being the best CRO in the world – measured by its employees, customers, investigators, and vendors. PSI’s hallmark is the on-time delivery of pivotal Phase II–III trials, with over 90% of projects delivered on schedule in 2025.

Specializing in oncology, hematology, gastroenterology, autoimmune, infectious diseases, neurology, and other complex therapeutic areas, PSI brings deep expertise in precision medicine, radiopharmaceuticals, and cell and gene therapy studies.

Founded in 1995 and privately owned, PSI employs 3,200 full-time professionals across 58 countries, with global headquarters in Zug, Switzerland.

http://www.psi-cro.com/

¹ Tufts CSDD, 2024: “Clinical Site Enrollment Performance Trends.”